Platelet Aggregation & Blood Pressure Regulation Pathways

"Platelet Aggregation & Blood Pressure Regulation Pathways" refers collectively to the complex interplay of molecular and cellular processes regulating platelet activation/aggregation and the control of vascular tone and blood pressure. Key molecular players include ADP receptors (such as P2Y1 and P2Y12 on platelets), enzymes generating thromboxane A2, vascular factors like nitric oxide, and components of the renin–angiotensin system. These pathways are central to hemostasis, thrombosis, and hypertension, and their dysregulation is implicated in diseases such as stroke and myocardial infarction. Pharmacological manipulation typically targets individual molecules within these pathways (e.g., antiplatelet drugs or antihypertensives), not the pathway as a whole[1][2][3][5]. This entry is not suitable as a single canonical therapeutic target; for drug discovery or biomarker purposes, it should be resolved into individual, validated molecular targets such as "P2Y12 receptor," "Cyclooxygenase-1," or "Angiotensin-converting enzyme."

Other names

Platelet activation and blood pressure signaling pathwaysPlatelet aggregation and hypertension pathways

Inhibition of COX1 (to reduce thromboxane A2 production, e.g., aspirin); P2Y12 receptor antagonism (e.g., clopidogrel) to block ADP-mediated platelet aggregation; Inhibition of thromboxane production or action; Modulation of endothelial NO production (for antiplatelet and vasoprotective effects)